SCHEMBL5526124

SCHEMBL5526124

CN1C(=O)C(C)(C)Nc2cc([N+](=O)[O-])ccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
GAA P10253 1/20 0.53
CASP3 P42574 2/20 0.49
CASP1 P29466 1/20 0.49
CASP4 P49662 1/20 0.49
CASP7 P55210 1/20 0.49
CASP9 P55211 1/20 0.49
CASP6 P55212 1/20 0.49
GFER P55789 1/20 0.48
AKR1B1 P15121 2/20 0.47
NR1H2 P55055 1/20 0.46
NR1H3 Q13133 1/20 0.46
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.43
NPC1 O15118 1/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43
CAPN9 O14815 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL757606 0.78 AR (0.45) ALDH1A1GAACASP3CASP1CASP4
SCHEMBL9590694 0.75 CASP1 (0.54) ALDH1A1GAACASP3CASP1CASP4
SCHEMBL15543815 0.74 CASP1 (0.53) ALDH1A1GAACASP3CASP1CASP4
SCHEMBL1950575 0.73 GAA (0.56) ALDH1A1GAAGFERLMNASMN1; SMN2
SCHEMBL14328385 0.72 AKR1B1 (0.49) ALDH1A1GAACASP3CASP1CASP4
SCHEMBL755345 0.72 MEN1 (0.49) ALDH1A1CASP3AKR1B1NPC1MAPT
SCHEMBL7754611 0.72 CAPN9 (0.49) ALDH1A1CASP3AKR1B1NPC1MAPT
SCHEMBL3592128 0.72 CASP1 (0.50) ALDH1A1GAACASP3CASP1CASP4
SCHEMBL15544539 0.72 CASP1 (0.50) ALDH1A1GAACASP3CASP1CASP4
SCHEMBL31419414 0.72 CASP1 (0.50) ALDH1A1GAACASP3CASP1CASP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167445-A1 Androgen receptor modulator compounds and methods LIGAND PHARMACEUTICALS, INC. 2007-07-19 US disclosed
EP-1212330-B1 ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARM INC (US) 2006-04-19 EP disclosed
US-20030186970-A1 Androgen receptor modulator compounds and methods LIGAND PHARMACEUTICALS, INC, 2003-10-02 US disclosed
US-6462038-B1 SUCH AS 1,2,3,6-TETRAHYDRO-1-METHYL-9-(TRIFLUOROMETHYL)-7H-(1,4)OXAZINO(3,2 -G)QUINOLIN-7-ONE; NONSTEROIDAL, HIGH AFFINITY AND SPECIFICITY ANTAGONISTS AND AGONISTS OR PARTIAL AGONISTS, I.E. PARTIAL AND/OR TISSUE SPECIFIC ACTIVATORS LIGAND PHARMACEUTICALS, INC. 2002-10-08 US disclosed
WO-2001016139-A9 ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARM INC (US) 2002-09-19 WO disclosed
EP-1212330-A1 ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS INCORPORATED (US) 2002-06-12 EP disclosed
WO-2001016139-A1 ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS INCORPORATED (US) 2001-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186970-A1 Androgen receptor modulator compounds and methods AR, NR5A1, FSHR ALDH1A1 1492/4885GAA 4776/4885CASP3 4702/4885
US-20070167445-A1 Androgen receptor modulator compounds and methods AR, NR5A1, FSHR ALDH1A1 1492/4885GAA 4776/4885CASP3 4702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.